-- 根据周一提交给印度证券交易所的文件显示，Rossari Biotech（NSE：ROSSARI，BOM：543213）第四财季归属于股东的合并利润从去年同期的3.444亿卢比跃升至4.597亿卢比。 该公司股价在近期交易中下跌近6%。 截至3月31日的季度，每股收益从去年同期的6.21卢比增至8.29卢比。 文件显示，这家化工公司的营业收入同比增长，从58亿卢比增至68.5亿卢比。 Rossari Biotech董事会建议派发截至3月31日财年的末期股息，每股0.50卢比。
Related Articles
International
Italy's Monthly Industrial Producer Prices Rise 4.4% in March
Italy's industrial producer prices rose 4.4% month over month in March, following a 0.4% decline in February, data from statistics agency Istat showed Tuesday.On a yearly basis, the index was up 4.2%, compared with the 2.7% drop earlier.
$^SXXP
Asia
Tigermed Consulting's Q1 Profit Slides 70%
Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) recorded a 70% decline in attributable profit in the first quarter of 2026 to 49 million yuan from 165.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Earnings per share slipped to 0.06 yuan from 0.19 yuan in the corresponding period of the previous fiscal year.The medical laboratory company's revenue jumped 15% to 1.8 billion yuan from 1.56 billion yuan in the year-ago period.
$HKG:3347$SHE:300347
Asia
LB Group's Attributable Profit Slides 73% in Q1
LB Group's (SHE:002601) attributable profit fell 73% to 187 million yuan in the first quarter from 686.1 million yuan in the year-ago period, according to a Tuesday filing with the Shenzhen bourse.Earnings per share at the titanium dioxide pigments manufacturer decreased 72% to 0.08 yuan from 0.29 yuan in the prior-year period.Operating revenue grew 1.4% year over year to 7.15 billion yuan from 7.05 billion yuan.
$SHE:002601